Thursday, 9 February 2012, 9.30 am - 11.00 am CET
SIX Swiss Exchange, ConventionPoint, Auditorium, Selnaustrasse 30, Zurich, Switzerland.
RSVP to Patricia Dal Pont, +41 43 211 42 14, patricia.dalpont@nobelbiocare.com.
This presentation will be audio-webcast live at www.nobelbiocare.com/investors and is also accessible via telephone conference. For the telephone conference, please dial in 10-15 minutes prior to the scheduled start using the following numbers (live-access to speakers for questions after the presentation):
+41 (0)91 610 56 00 Continental Europe
+44 (0)203 059 58 62 UK
+1 (1)866 291 41 66 USA
For additional local dial-in numbers please refer to the separate list:
Recording of the webcast will be available on the website shortly after the end of the conference.
The Full Year Results 2011 of Nobel Biocare will be published on 9 February 2012, at around 6.45 am CET.
Tel: +41 43 211 42 30; +41 79 430 81 46
E-mail:suha.demokan@nobelbiocare.com
Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutions from tooth to root, for single tooth to completely edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActive™, Brånemark System® and NobelReplace®), individualized prosthetics and equipment (NobelProcera™), guided surgerysolutions and biomaterials. Nobel Biocare has more than 2,400 employees and recorded revenue of EUR 576.6 million in 2010. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 34 direct sales organizations.
Disclaimer
This media release contains forward-looking statements
based on beliefs of Nobel Biocare's management. When
used in this media release, words such as
"anticipate", "believe",
"estimate", "expect",
"intend", "plan" and
"project" are intended to identify
forward-looking statements. They may involve risks and
uncertainties, including technological advances in the
medical field, product demand and market acceptance, the
effect of economic conditions, the impact of competitive
products and pricing, foreign currency exchange rates and
other risks. These forward-looking statements reflect the
views of Nobel Biocare as of the date made with respect
to future events and are subject to risks and
uncertainties. All of these forward-looking statements
are based on estimates and assumptions made by management
of the company and are believed to be reasonable, though
are inherently uncertain and difficult to predict. Actual
results or experience could differ materially from the
forward-looking statements. Nobel Biocare disclaims any
intention or obligation to update these forward-looking
statements.